| scholarly article | Q13442814 |
| P50 | author | Goutham Narla | Q72345872 |
| Huma Rana | Q84265636 | ||
| P2093 | author name string | Eric Yuan | |
| Katerina Politi | |||
| Michael Ohlmeyer | |||
| Matthew Galsky | |||
| Analisa Difeo | |||
| David Burstein | |||
| Heather Melville | |||
| David Zhang | |||
| Sudeh Izadmehr | |||
| Neil S Dhawan | |||
| Jaya Sangodkar | |||
| Sahar Mazhar | |||
| Suzanna Katz | |||
| Caroline Farrington | |||
| Varan J Singh | |||
| Pearlann Arnovitz | |||
| Rachel Okrent | |||
| Tara Albano | |||
| P2860 | cites work | KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib | Q21563446 |
| A module of negative feedback regulators defines growth factor signaling | Q45345602 | ||
| Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer | Q46051178 | ||
| Differentially expressed genes in nonsmall cell lung cancer: expression profiling of cancer-related genes in squamous cell lung cancer | Q47906539 | ||
| Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination. | Q54596671 | ||
| Search for Large Extra Dimensions in Dielectron and Diphoton Production | Q56942433 | ||
| Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor | Q22009126 | ||
| Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex | Q24295120 | ||
| Phosphorylation of serine 256 suppresses transactivation by FKHR (FOXO1) by multiple mechanisms. Direct and indirect effects on nuclear/cytoplasmic shuttling and DNA binding | Q24306703 | ||
| Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain | Q24794765 | ||
| EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy | Q27824812 | ||
| EGFR mutation and resistance of non-small-cell lung cancer to gefitinib | Q27824829 | ||
| MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 | ||
| Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors | Q27851633 | ||
| Cancer statistics, 2010 | Q27860525 | ||
| PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR | Q28240702 | ||
| FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis | Q28285131 | ||
| Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo | Q28476362 | ||
| Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems | Q28586004 | ||
| Erlotinib in previously treated non-small-cell lung cancer | Q29547546 | ||
| Gene-expression profiles predict survival of patients with lung adenocarcinoma | Q29614443 | ||
| Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses | Q29616071 | ||
| EGF-ERBB signalling: towards the systems level | Q29619032 | ||
| Krüppel-like factor 6 is frequently down-regulated and induces apoptosis in non-small cell lung cancer cells. | Q30762846 | ||
| Integrative genomic approaches identify IKBKE as a breast cancer oncogene | Q33287979 | ||
| Phosphatidylinositol 3-kinase signaling in proliferating cells maintains an anti-apoptotic transcriptional program mediated by inhibition of FOXO and non-canonical activation of NFkappaB transcription factors | Q33316851 | ||
| Targeted reduction of KLF6-SV1 restores chemotherapy sensitivity in resistant lung adenocarcinoma. | Q33699499 | ||
| Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors | Q34666826 | ||
| PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer | Q36278234 | ||
| FOXO transcription factors: key regulators of cell fate | Q36628599 | ||
| Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. | Q37010442 | ||
| The role of KLF6 and its splice variants in cancer therapy | Q37355353 | ||
| Proteasomal degradation of the FoxO1 transcriptional regulator in cells transformed by the P3k and Akt oncoproteins | Q37535142 | ||
| MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo | Q38431323 | ||
| FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. | Q39571776 | ||
| Inferring dynamic gene networks under varying conditions for transcriptomic network comparison. | Q39733251 | ||
| Expression and localization of FOXO1 in non-small cell lung cancer. | Q39840324 | ||
| AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl | Q40093939 | ||
| Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma | Q40130158 | ||
| Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor | Q40164535 | ||
| Somatic activation of the K-ras oncogene causes early onset lung cancer in mice | Q40809826 | ||
| Phosphorylation and nuclear exclusion of the forkhead transcription factor FKHR after epidermal growth factor treatment in human breast cancer cells. | Q40849405 | ||
| A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells | Q44714283 | ||
| PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. | Q44846498 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2637-2651 | |
| P577 | publication date | 2012-06-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response | |
| P478 | volume | 122 |
| Q35137291 | A Krüppel-like factor downstream of the E3 ligase WWP-1 mediates dietary-restriction-induced longevity in Caenorhabditis elegans |
| Q30252408 | Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth. |
| Q90400032 | Antipsychotic Drug Trifluoperazine Suppresses Colorectal Cancer by Inducing G0/G1 Arrest and Apoptosis |
| Q91272140 | Artesunate induces mitochondria-mediated apoptosis of human retinoblastoma cells by upregulating Kruppel-like factor 6 |
| Q34752876 | Bisphosphonates inactivate human EGFRs to exert antitumor actions |
| Q64298569 | CDRgator: An Integrative Navigator of Cancer Drug Resistance Gene Signatures |
| Q103002157 | Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma |
| Q55220408 | Clinical significance of blood-based miRNAs as biomarkers of non-small cell lung cancer. |
| Q40366394 | Comparative mutational landscape analysis of patient-derived tumour xenografts |
| Q36363841 | Conformational stabilization of FOX-DNA complex architecture to sensitize prostate cancer chemotherapy |
| Q39120126 | Curcumin inhibits lung cancer progression and metastasis through induction of FOXO1. |
| Q35695511 | Dedifferentiation of patient-derived glioblastoma multiforme cell lines results in a cancer stem cell-like state with mitogen-independent growth |
| Q64120213 | Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma |
| Q64376260 | Dysregulation of Krüppel-like factor 12 in the development of endometrial cancer |
| Q99571193 | FUT4siRNA augments the chemosensitivity of non-small cell lung cancer to cisplatin through activation of FOXO1-induced apoptosis |
| Q36223164 | Integrated discovery of FOXO1-DNA stabilizers from marine natural products to restore chemosensitivity to anti-EGFR-based therapy for metastatic lung cancer |
| Q39849534 | Isorhapontigenin (ISO) Inhibits Invasive Bladder Cancer Formation In Vivo and Human Bladder Cancer Invasion In Vitro by Targeting STAT1/FOXO1 Axis |
| Q38031130 | Kruppel-Like Factors and Vascular Inflammation: Implications for Atherosclerosis |
| Q38141516 | Krüppel-like factors in cancer |
| Q89542605 | Loss of tumor suppressor IGFBP4 drives epigenetic reprogramming in hepatic carcinogenesis |
| Q90639806 | Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells |
| Q38938528 | MiR-135b promotes proliferation and invasion of osteosarcoma cells via targeting FOXO1. |
| Q39210882 | MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine |
| Q36305862 | Oncogenic miR-9 is a target of erlotinib in NSCLCs |
| Q38722976 | Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies. |
| Q34942420 | Phenothiazine Inhibitors of TLKs Affect Double-Strand Break Repair and DNA Damage Response Recovery and Potentiate Tumor Killing with Radiomimetic Therapy |
| Q37524180 | Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia. |
| Q90339355 | Protein phosphatase 2A controls ongoing DNA replication by binding to and regulating cell division cycle 45 (CDC45) |
| Q34752800 | Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer |
| Q35536672 | Repurposing the antipsychotic trifluoperazine as an antimetastasis agent |
| Q36413425 | Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways |
| Q26796409 | Roles of transcriptional factor 7 in production of inflammatory factors for lung diseases |
| Q37194856 | Survival of HER2-Positive Breast Cancer Cells: Receptor Signaling to Apoptotic Control Centers |
| Q38194591 | Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond |
| Q34987170 | Targeting myristoylated alanine-rich C kinase substrate phosphorylation site domain in lung cancer. Mechanisms and therapeutic implications |
| Q34398166 | Targeting nucleocytoplasmic transport in cancer therapy |
| Q35626151 | The role of c-Src in the invasion and metastasis of hepatocellular carcinoma cells induced by association of cell surface GRP78 with activated α2M |
| Q35037262 | Therapeutic Re-Activation of Protein Phosphatase 2A in Acute Myeloid Leukemia |
| Q47436859 | Therapeutic Targeting of PP2A. |
| Q57073895 | Trifluoperazine prevents FOXO1 nuclear excretion and reverses doxorubicin-resistance in the SHG44/DOX drug-resistant glioma cell line |
| Q55434033 | [The targets research of non-small cell lung cancer targeted therapy]. |
Search more.